Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

Looking for dividend income? Explore these high-paying dividend stocks from the S&P 500 for potential returns in 2025.

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when ...

Last year was one for the record books for Chevron ( CVX 0.63%). The energy giant increased its global production by 7% and U.S. output by 19% to record levels. The company also returned a record $27 ...

Deutsche Börse grows 15% YoY with strong revenues, aiming for €6B by 2025. Learn more about DBOEF stock's strategy, dividend ...

Still, Wood said it expects to return to positive free cash flow next year, and some disposals will help support its balance sheet. Even with uncertainties, "management being in a position to say ...

Enterprise Products Partners ended last year with a 3.1 times leverage ratio. That was well within its target range of 2.75 ...

This article was first published in the Department of Agricultural Economics’ “Cornhusker Economics” series on Feb. 5, 2025. Tim Meyer is an associate professor of practice in the Department of ...

Julius Berger Nigeria Plc’s 2024 financials tell a story of contradictions; soaring revenues and strategic expansion juxtaposed with dwindling liquidity.

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, has significantly improved its revenues and strengthened its balance sheet.